Q1 FY27: PAT up 5x to Rs 3.75 cr on margin gains, revenue dips 3%

Profit growth above 25%Revenue declinedRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.6%Reaction day

₹220.10

prior close

₹220.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+5.5% vs market

Edible Oil peers, median of 21sector-0.5%+6.1% vs sector

On the reaction day the stock moved 5.5 pts more than Nifty Microcap 250 and 6.1 pts more than its Edible Oil peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.6+0.1+5.5-0.5+6.1

Next day

+8.0+0.5+7.5-0.7+8.7

+14.4-0.1+14.5-1.6+16.1

+28.1+0.4+27.7-1.4+29.5

+18.6+0.7+17.9-1.8+20.4

+17.7+0.9+16.7-0.6+18.2

+9.2+1.1+8.1-1.5+10.7

15d

+6.8+1.6+5.2-2.2+9.0

+2.6-0.7+3.3-4.8+7.4

—-3.2—-6.5—

—————

UpDownMarket · Nifty Microcap 250Sector · Edible Oil peers, median of 21Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ambar Protein Industries Q1 FY27 revenue fell 3.3% to Rs 113.45 cr from Rs 117.27 cr a year ago. PAT jumped to Rs 3.75 cr from Rs 0.75 cr, with EPS rising to Rs 6.53 from Rs 1.30, helped by lower raw material costs. Board approved related party sale of machinery to Ankur Oil Industries and a revision in Managing Director and Whole Time Director remuneration, both needing shareholder approval at the 33rd AGM on September 30, 2026.

Likely market impact

Strong profit growth despite revenue dip shows better cost control. Related party deals and director pay revision need shareholder approval.